암백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cancer Vaccines Market size is expected to reach USD 27.75 Billion in 2034 from USD 10.67 Billion (2025) growing at a CAGR of 11.21% during 2026-2034.

The Global Cancer Vaccines Market is gaining significant attention as researchers focus on developing innovative immunotherapy solutions to prevent and treat cancer. Cancer vaccines work by stimulating the immune system to recognize and attack cancer cells, offering a targeted and potentially less invasive treatment approach. Increasing global cancer incidence and growing demand for advanced treatment options are contributing to the expansion of this market.

One of the major drivers of the market is the rapid advancement of immunotherapy and biotechnology research. Pharmaceutical companies and research institutions are investing heavily in the development of therapeutic and preventive cancer vaccines. Improved understanding of tumor biology and immune responses has enabled the creation of vaccines that target specific cancer antigens, improving treatment effectiveness and reducing side effects compared to conventional therapies.

The future of the cancer vaccines market looks promising with ongoing clinical trials and breakthroughs in personalized medicine. Emerging technologies such as mRNA-based vaccines and combination therapies are expected to revolutionize cancer treatment. As healthcare systems increasingly adopt innovative immunotherapy solutions, cancer vaccines are likely to play a vital role in the next generation of oncology treatments.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
• Others

By Indication Type

• Prostate Cancer
• Bladder Cancer
• Melanoma
• Cervical Cancer
• Other

By Technology Type

• Recombinant Cancer Vaccines
• Whole-cell Cancer Vaccines
• Viral Vector and DNA Cancer Vaccines
• Other Technologies

COMPANIES PROFILED

• Merck Co Inc, GSK plc, Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, Ferring BV, Amgen Inc, Moderna Inc, Sanofi, AstraZeneca, Bristol Myers Squibb
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER VACCINES MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Vaccine Type
• 4.2. Preventive Cancer Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Therapeutic Cancer Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL CANCER VACCINES MARKET: BY INDICATION TYPE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Indication Type
• 5.2. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL CANCER VACCINES MARKET: BY TECHNOLOGY TYPE 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Technology Type
• 6.2. Recombinant Cancer Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Whole-cell Cancer Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Viral Vector and DNA Cancer Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.5. Other Technologies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL CANCER VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Vaccine Type
  • 7.2.2 By Indication Type
  • 7.2.3 By Technology Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Vaccine Type
  • 7.3.2 By Indication Type
  • 7.3.3 By Technology Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Vaccine Type
  • 7.4.2 By Indication Type
  • 7.4.3 By Technology Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Vaccine Type
  • 7.5.2 By Indication Type
  • 7.5.3 By Technology Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Vaccine Type
  • 7.6.2 By Indication Type
  • 7.6.3 By Technology Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER VACCINES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Merck & Co. Inc
  • 9.2.2 GSK Plc
  • 9.2.3 Dendreon Pharmaceuticals LLC
  • 9.2.4 Dynavax Technologies Corporation
  • 9.2.5 Ferring B.V
  • 9.2.6 Amgen Inc
  • 9.2.7 Moderna Inc
  • 9.2.8 Sanofi
  • 9.2.9 AstraZeneca
  • 9.2.10 Bristol Myers Squibb